Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20226663 | 0.85 | MAPT (0.40) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL23140222 | 0.83 | MAPT (0.41) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL19121034 | 0.83 | MAPT (0.39) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL21152760 | 0.83 | MAPT (0.39) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL19403535 | 0.83 | MME (0.32) | MAPTGAAALDH1A1ALOX12MME | |
| SCHEMBL22166373 | 0.80 | MME (0.33) | ALDH1A1MME | |
| SCHEMBL21152368 | 0.80 | ALDH1A1 (0.37) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL24966963 | 0.79 | MAPT (0.33) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL16449757 | 0.79 | ALDH1A1 (0.30) | MAPTGAAALDH1A1ALOX12 | |
| SCHEMBL12381788 | 0.79 | SMN1; SMN2 (0.36) | MAPTGAAALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024013723-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | disclosed |
| US-11857638-B2 | Quinone-containing conjugates | PROMEGA CORPORATION (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857638-B2 | Quinone-containing conjugates | PROMEGA CORPORATION (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-7326793-B2 | From a pyrrolidinone compound; coloring high molecular weight material | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070117889-A1 | Process for the direct preparation of pyrrolo[3,4-C]pyrroles | RUFFIEUX VINCENT | 2007-05-24 | — | — | US | disclosed |
| EP-1425282-B1 | PROCESS FOR THE PREPARATION OF DIKETOPYRROLOPYRROLES | CIBA SC HOLDING AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| US-7186847-B2 | From a pyrrolidinone compound; coloring high molecular weight material | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20040249162-A1 | From a pyrrolidinone compound; coloring high molecular weight material | BASF SE (DE) | 2004-12-09 | — | — | US | disclosed |
| US-20040171847-A1 | From a pyrrolidinone compound; coloring high molecular weight material | CIBA SPECIALTY CHEMICALS CORP. | 2004-09-02 | — | — | US | disclosed |
| EP-1436296-A2 | PROCESS FOR THE DIRECT PREPARATION OF PYRROLO 3,4-C]PYRROLES | Ciba SC Holding AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| EP-1425282-A2 | PROCESS FOR THE PREPARATION OF DIKETOPYRROLOPYRROLES | Ciba SC Holding AG (CH) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022848-A2 | PROCESS FOR THE PREPARATION OF DIKETOPYRROLOPYRROLES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022847-A2 | PROCESS FOR THE DIRECT PREPARATION OF PYRROLO[3,4-C]PYRROLES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | MAPT 3713/4885GAA 2646/4885ALDH1A1 3778/4885 |
| US-20040249162-A1 | From a pyrrolidinone compound; coloring high molecular weight material | PAXBP1, PAX3, PPOX | MAPT 1138/4885GAA 3917/4885ALDH1A1 681/4885 |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | TOP2A, TOP1, XPA | MAPT 3303/4885GAA 1021/4885ALDH1A1 1163/4885 |
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | MAPT 3123/4885GAA 335/4885ALDH1A1 4494/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | MAPT 3354/4885GAA 12/4885ALDH1A1 72/4885 |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | EPCAM, IGSF11, FCGR3B | MAPT 1237/4885GAA 1066/4885ALDH1A1 1539/4885 |
| US-20070117889-A1 | Process for the direct preparation of pyrrolo[3,4-C]pyrroles | PAX3, PPOX, FIP1L1 | MAPT 515/4885GAA 3810/4885ALDH1A1 339/4885 |
| US-11857638-B2 | Quinone-containing conjugates | NQO1, NQO2, SQOR | MAPT 2456/4885GAA 380/4885ALDH1A1 460/4885 |
| US-20040171847-A1 | From a pyrrolidinone compound; coloring high molecular weight material | MKI67, PAH, PKLR | MAPT 2491/4885GAA 808/4885ALDH1A1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.